DK2500036T3 - MET-hæmmere til øgning af virkningen af radioterapi - Google Patents

MET-hæmmere til øgning af virkningen af radioterapi

Info

Publication number
DK2500036T3
DK2500036T3 DK11158861.2T DK11158861T DK2500036T3 DK 2500036 T3 DK2500036 T3 DK 2500036T3 DK 11158861 T DK11158861 T DK 11158861T DK 2500036 T3 DK2500036 T3 DK 2500036T3
Authority
DK
Denmark
Prior art keywords
radiotherapy
increase
effect
met inhibitors
inhibitors
Prior art date
Application number
DK11158861.2T
Other languages
Danish (da)
English (en)
Inventor
Paolo Maria Comoglio
Carla Boccaccio
Fiorella Petronzelli
Santis Rita De
Original Assignee
Metheresis Translational Res Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metheresis Translational Res Sa filed Critical Metheresis Translational Res Sa
Application granted granted Critical
Publication of DK2500036T3 publication Critical patent/DK2500036T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
DK11158861.2T 2011-03-18 2011-03-18 MET-hæmmere til øgning af virkningen af radioterapi DK2500036T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11158861.2A EP2500036B1 (en) 2011-03-18 2011-03-18 MET inhibitors for enhancing radiotherapy efficacy

Publications (1)

Publication Number Publication Date
DK2500036T3 true DK2500036T3 (da) 2014-08-04

Family

ID=44260211

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11158861.2T DK2500036T3 (da) 2011-03-18 2011-03-18 MET-hæmmere til øgning af virkningen af radioterapi

Country Status (22)

Country Link
US (1) US20120237524A1 (enExample)
EP (1) EP2500036B1 (enExample)
JP (1) JP5671487B2 (enExample)
KR (1) KR101540838B1 (enExample)
CN (1) CN102688491A (enExample)
AU (1) AU2012201303B2 (enExample)
BR (1) BR102012006063B1 (enExample)
CA (1) CA2769991C (enExample)
CY (1) CY1115374T1 (enExample)
DK (1) DK2500036T3 (enExample)
EA (1) EA028590B1 (enExample)
ES (1) ES2489475T3 (enExample)
HR (1) HRP20140729T1 (enExample)
IL (1) IL218293A (enExample)
MX (1) MX2012003084A (enExample)
PL (1) PL2500036T3 (enExample)
PT (1) PT2500036E (enExample)
RS (1) RS53468B (enExample)
SG (1) SG184637A1 (enExample)
SI (1) SI2500036T1 (enExample)
SM (1) SMT201400106B (enExample)
ZA (1) ZA201201992B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗met抗體,結合met之雙特異性抗原結合分子及其使用方法
IT201800009282A1 (it) * 2018-10-09 2020-04-09 Metis Prec Medicine Sb Srl Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi
CN110320365B (zh) * 2019-07-06 2022-07-22 湖南莱拓福生物科技有限公司 NF-κB RelA/p65蛋白位点特异性磷酸化诊断试剂盒
US11896682B2 (en) 2019-09-16 2024-02-13 Regeneron Pharmaceuticals, Inc. Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ras抑制劑
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
BRPI0407446A (pt) * 2003-02-13 2006-01-31 Pharmacia Corp Anticorpos para c-met para o tratamento de cânceres
EP1648998B1 (en) * 2003-07-18 2014-10-01 Amgen Inc. Specific binding agents to hepatocyte growth factor
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
EP1981981B1 (en) * 2006-02-06 2011-06-29 Metheresis Translational Research SA Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products
EP2019116A1 (en) * 2007-07-26 2009-01-28 Helmholtz-Zentrum für Infektionsforschung GmbH Inhibitor of the met-receptor and its use

Also Published As

Publication number Publication date
CA2769991C (en) 2018-05-15
RS53468B (sr) 2014-12-31
CA2769991A1 (en) 2012-09-18
AU2012201303B2 (en) 2013-11-07
AU2012201303A1 (en) 2012-10-04
KR20120106582A (ko) 2012-09-26
CY1115374T1 (el) 2017-01-04
SG184637A1 (en) 2012-10-30
EA201200329A3 (ru) 2013-01-30
ES2489475T3 (es) 2014-09-02
PT2500036E (pt) 2014-08-25
IL218293A (en) 2016-06-30
HRP20140729T1 (hr) 2014-08-29
JP2012196206A (ja) 2012-10-18
PL2500036T3 (pl) 2014-10-31
EA201200329A2 (ru) 2012-09-28
IL218293A0 (en) 2012-07-31
BR102012006063A2 (pt) 2021-11-16
SMT201400106B (it) 2014-11-10
KR101540838B1 (ko) 2015-08-06
US20120237524A1 (en) 2012-09-20
HK1174539A1 (en) 2013-06-14
JP5671487B2 (ja) 2015-02-18
CN102688491A (zh) 2012-09-26
EP2500036B1 (en) 2014-05-07
MX2012003084A (es) 2012-09-17
BR102012006063A8 (pt) 2022-11-08
SI2500036T1 (sl) 2014-09-30
EP2500036A1 (en) 2012-09-19
EA028590B1 (ru) 2017-12-29
BR102012006063B1 (pt) 2023-03-07
ZA201201992B (en) 2015-05-27

Similar Documents

Publication Publication Date Title
SMT201700109B (it) Inibitori di istone demetilasi
DK2500036T3 (da) MET-hæmmere til øgning af virkningen af radioterapi
EP2683693A4 (en) ROR-GAMMA-T INHIBITORS
SMT201700094B (it) Composto di pirazina carbossammide
SMT201700111B (it) Eterociclilammine come inibitori di pi3k
IL227764A0 (en) Pyrrolotriazinone derivatives as pi3k inhibitors
CO7010824A2 (es) Inhibidores de aplicación viral
CO6930358A2 (es) Compuestos inhibidores de metaloenzimas
EP2675909A4 (en) GLUCOSYLSTEVIA COMPOSITION
EP2720561A4 (en) Stevia-COMPOSITION
HUE040455T2 (hu) T-sejt aktiválás inhibitorai
EP2713762A4 (en) Stevia-COMPOSITION
CO6920291A2 (es) 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idhmutante
DK3520805T3 (da) Sammensætninger til behandling af myelofibrose
DK2755481T3 (da) Anvendelse af alginatoligomerer til at forøge virkningerne af svampemidler
DK2804858T3 (da) Metalloenzym-inhibitorforbindelser
HRP20180809T1 (hr) Inhibicijski spojevi metaloenzima
BR112014013850A2 (pt) conjunto de prateleiras
DK2928477T3 (da) Anvendelse af telomeraseinhibitor imetelstat til behandling af myelofibrosis
SMT201600328B (it) Nuovi composti come inibitori di diacilglicerolo aciltransferasi
HRP20182043T8 (hr) Upotreba anti-koneksinskih sredstava za poboljšanje terapijskog učinka inhibitora acetilkolinesteraze
SI2833884T1 (sl) Uporaba CCR3-inhibitorjev
EP2858975A4 (en) FBXO3 INHIBITORS
EP2770998A4 (en) Factor ixa inhibitors
DK2888228T3 (da) Inhibitorer af CD40-TRAF6 interaktion